CDT Equity Q1 2026: $4.1M Loss, $0.1M Cash, Going Concern Warning Reiterated
CDT is trading near its 52-week low of $0.34 (3.0% above the low).
Summary
CDT Equity's Q1 2026 filing reveals a cash crisis: $97,000 left, a going concern warning, and ongoing reliance on dilutive financing. The company's survival hinges on raising capital, but existing shareholders face severe dilution.
Key Events · Earnings and Guidance · CDT
-
Going Concern Warning Reiterated
Management states substantial doubt about CDT's ability to continue as a going concern, with only $97,000 in cash and a $72.4 million accumulated deficit as of March 31, 2026.
-
Q1 2026 Net Loss of $4.1 Million
The company reported a net loss of $4.1 million for the quarter, with operating expenses of $3.7 million and negative operating cash flow of $1.9 million.
-
Sarborg Investment Dominates Balance Sheet
A $122.9 million equity method investment in Sarborg represents nearly all of CDT's assets, but the company still owes $8 million in cash for the acquisition and must raise $20 million to pay it.
-
Material Weaknesses in Internal Controls
Disclosure controls and procedures remain ineffective due to previously identified material weaknesses that have not been remediated.
Analysis · CDT · Life Sciences
CDT Equity's Q1 2026 report confirms the company is in a precarious financial position. With only $97,000 in cash and a $72.4 million accumulated deficit, management reiterates substantial doubt about its ability to continue as a going concern. The company burned $1.9 million in operations during the quarter and relies on dilutive financing to survive. A $122.9 million equity method investment in Sarborg dominates the balance sheet, but its value is tied to a volatile stock price and an $8 million cash payment still owed. Subsequent events show continued reliance on toxic convertible debt and ATM sales, further diluting existing shareholders. The stock trades near its 52-week low, reflecting the market's assessment of these risks.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 44% of the 562 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.34 to $468.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.